NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Epitopoietic Research Corporation
Innovent Biologics (Suzhou) Co. Ltd.
National Institutes of Health Clinical Center (CC)
Celldex Therapeutics
Children's Oncology Group
M.D. Anderson Cancer Center
Children's Oncology Group
National Cancer Institute (NCI)